Chengdu Kanghong Pharmaceutical Group Co., Ltd

Shenzhen Stock Exchange 002773.SZ

Chengdu Kanghong Pharmaceutical Group Co., Ltd Return on Equity (ROE) for the year ending December 31, 2023: 13.39%

Chengdu Kanghong Pharmaceutical Group Co., Ltd Return on Equity (ROE) is 13.39% for the year ending December 31, 2023, a 3.05% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Chengdu Kanghong Pharmaceutical Group Co., Ltd Return on Equity (ROE) for the year ending December 31, 2022 was 12.99%, a 87.89% change year over year.
Chengdu Kanghong Pharmaceutical Group Co., Ltd Return on Equity (ROE) for the year ending December 31, 2021 was 6.91%, a 247.49% change year over year.
Chengdu Kanghong Pharmaceutical Group Co., Ltd Return on Equity (ROE) for the year ending December 31, 2020 was -4.69%, a -130.16% change year over year.
Chengdu Kanghong Pharmaceutical Group Co., Ltd Return on Equity (ROE) for the year ending December 31, 2019 was 15.54%, a -8.66% change year over year.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

Shenzhen Stock Exchange: 002773.SZ

Chengdu Kanghong Pharmaceutical Group Co., Ltd

CEO	Mr. Xiao Ke
IPO Date	June 29, 2015
Location	China
Headquarters	No.36, Shuxi Road
Employees	4,289
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Chengdu Kanghong Pharmaceuticals Group Co., Ltd engages in the research, development, production, and sale of biological products, Chinese medicines, and chemical drugs in China. It offers ophthalmic systems, central nervous systems, digestive systems, and other system drugs. The company was founded in 1996 and is headquartered in Chengdu, China.

Key trends

Past 5 years